Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 4
---
 very limited rights and is effectively valueless. The B deferred shares have the rights and restrictions as set out in the
Articles of Association and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company
or to receive a dividend or other distribution.

On July 5, 2023, and in an
effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a
ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and
in an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024,
we held a general meeting of shareholders, or November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares
of £0.001 nominal value each into one ordinary share of £0.00005 nominal value and 19 C deferred shares of £0.00005
nominal value each, each the November Subdivision, and (y) adopt new Articles of Association, which made consequential amendments to
the existing Articles of Association of the Company to reflect the November Subdivision. As is standard for deferred shares, each C deferred
share has very limited rights and is effectively valueless. The C deferred shares have the rights and restrictions as set out in the
Articles of Association and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company
or to receive a dividend or other distribution.

| 2 |

On June 11, 2025, we
held a general meeting of shareholders, or June 2025 GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares
of £0.00005 nominal value each into one ordinary share of £0.000001 nominal value and 49 D deferred shares of £0.000001
nominal value each, each the June 2025 Subdivision, and (y) adopt new Articles of Association, which made consequential amendments